No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
www.santhera.comNo one on the platform currently holds SANN.SW.
No tracked institution reports a position in SANN.SW as of their last filing.
No one on the platform has traded SANN.SW yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | 97.3% | 38.8% | ||||
| Profit Margin % | -63.8% | 482.4% | 135.4% | |||
| Free Cash Flow Margin % | -45.1% | |||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $95M | +22.4% | $-1.21 | $-2.50–$0.09 | — | 1 |
| 2027 | $116M | +22.0% | $0.17 | $-0.40–$0.74 | — | 1 |
| 2028 | $128M | +10.9% | $0.29 | $0.26–$0.31 | — | 1 |
| 2029 | $189M | +47.5% | $3.04 | $2.74–$3.35 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 1 of the last 6 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-04-28 | $-0.09 | $-0.79 | -777.8% |
| 2025-09-15 | $-0.60 | $-3.04 | -406.7% |
| 2025-04-29 | $-0.74 | $-2.09 | -182.4% |
| 2024-09-12 | $-0.94 | $-1.35 | -43.6% |
| 2023-04-27 | $0.08 | $-6.43 | -8137.5% |
| 2022-06-10 | $-7.60 | $-7.60 | +0.0% |
| -2.30% |
| $478M |
| — |
| EVE.SWEvoNext Holdings S.A. | $2.05 | -8.89% | $15M | — |
| MOLN.SWMolecular Partners AG | $3.27 | -1.80% | $123M | — |
Source: Financial Modeling Prep · peers by sector/industry